Tin tức & Cập nhật
Lọc theo Chuyên ngành:

Ipilimumab plus nivolumab elicits response in mCRPC
Use of dual immune checkpoint inhibitors (ICIs), nivolumab and ipilimumab, exhibits responses in some molecularly selected patients with metastatic castration-resistant prostate cancer (mCRPC), including those with mismatch repair deficiency (dMMR), nonsynonymous tumour mutational burden ≥7.1 muts/Mb (hTMB), a BRCA2 mutation (BRCAm), or biallelic CDK12 inactivation (CDK12i).
Ipilimumab plus nivolumab elicits response in mCRPC
02 Jan 2025
Salbutamol may lower risk, improve prognosis of prostate cancer
The incidence of prostate cancer is reduced among individuals treated with salbutamol, a short-acting beta-2 adrenergic agonist, according to a study.
Salbutamol may lower risk, improve prognosis of prostate cancer
14 Dec 2024
Older men receiving aggressive prostate cancer treatment growing in number
In the past 2 decades, more and more men have been overtreated for intermediate- and high-risk prostate cancer despite having limited life expectancy, according to a large study.
Older men receiving aggressive prostate cancer treatment growing in number
16 Nov 2024
Topical estriol gel prevents UTI, improves vaginal health in postmenopausal women
Ultra-low-dose 0.005 % estriol vaginal gel helps reduce the incidence of recurrent urinary tract infections (UTIs) and improve vaginal pH in postmenopausal women with genitourinary syndrome of menopause (GSM), as reported in a study.